C/EBPβ isoform-specific regulation of podocyte pyroptosis in lupus nephritis-induced renal injury
Huimei Zou, Min Chen, Xiuhong Wang, Jie Yu, Xiaoying Li, Ying Xie, Jun Liu, Miao Liu, Lifen Xu, Qiong Zhang, Xiaoxue Tian, Fan Zhang, Bing Guo
求助PDF
{"title":"C/EBPβ isoform-specific regulation of podocyte pyroptosis in lupus nephritis-induced renal injury","authors":"Huimei Zou, Min Chen, Xiuhong Wang, Jie Yu, Xiaoying Li, Ying Xie, Jun Liu, Miao Liu, Lifen Xu, Qiong Zhang, Xiaoxue Tian, Fan Zhang, Bing Guo","doi":"10.1002/path.6174","DOIUrl":null,"url":null,"abstract":"<p>As an essential factor in the prognosis of systemic lupus erythematosus (SLE), lupus nephritis (LN) can accelerate the rate at which patients with SLE can transition to chronic kidney disease or even end-stage renal disease. Podocytes now appear to be a possible direct target in LN in addition to being prone to collateral damage from glomerular capillary lesions induces by immune complexes and inflammatory processes. The NLRP3 inflammasome is regulated by CCAAT/enhancer-binding protein β (C/EBPβ), which is involved in the pathogenesis of SLE. However, the role and mechanism of C/EBPβ in LN remain unclear. In this investigation, glomerular podocytes treated with LN serum and MRL/lpr mice were employed as <i>in vivo</i> and <i>in vitro</i> models of LN, respectively. <i>In vivo</i>, the expression of C/EBPβ isoforms was detected in kidney specimens of humans and mice with LN. Then we assessed the effect of C/EBPβ inhibition on renal structure and function by injecting RNAi adeno-associated virus of C/EBPβ shRNA into MRL/lpr mice. <i>In vitro</i>, glomerular podocytes were treated with LN serum and C/EBPβ siRNA to explore the role of C/EBPβ in the activation of the AIM2 inflammasome and podocyte injury. C/EBPβ-LAP and C/EBPβ-LIP were significantly overexpressed in kidney tissue samples from LN patients and mice, and C/EBPβ inhibition significantly alleviated renal function damage and ameliorated renal structural deficiencies. Inflammatory pathways downstream from the AIM2 inflammasome could be suppressed by C/EBPβ knockdown. Furthermore, the upregulation of C/EBPβ-LAP could activate the AIM2 inflammasome and podocyte pyroptosis by binding to the promoters of <i>AIM2</i> and <i>CASPASE1</i> to enhance their expression, and the knockdown of AIM2 or (and) caspase-1 reversed the effects of C/EBPβ-LAP overexpression. Interestingly, C/EBPβ-LIP overexpression could transcriptionally inhibit IRAG and promote Ca<sup>2+</sup> release-mediated activation of the AIM2 inflammasome. This finding suggests that C/EBPβ is not only involved in the regulation of the expression of key proteins of the AIM2 inflammasome but also affects the polymerization of key proteins of the AIM2 inflammasome through the regulation of Ca<sup>2+</sup> release. In conclusion, this study provides a new idea for studying the regulatory mechanism of C/EBPβ and provides a theoretical basis for the early diagnosis and treatment of LN in the future. © 2023 The Pathological Society of Great Britain and Ireland.</p>","PeriodicalId":232,"journal":{"name":"The Journal of Pathology","volume":"261 3","pages":"269-285"},"PeriodicalIF":5.6000,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Pathology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/path.6174","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
引用
批量引用
Abstract
As an essential factor in the prognosis of systemic lupus erythematosus (SLE), lupus nephritis (LN) can accelerate the rate at which patients with SLE can transition to chronic kidney disease or even end-stage renal disease. Podocytes now appear to be a possible direct target in LN in addition to being prone to collateral damage from glomerular capillary lesions induces by immune complexes and inflammatory processes. The NLRP3 inflammasome is regulated by CCAAT/enhancer-binding protein β (C/EBPβ), which is involved in the pathogenesis of SLE. However, the role and mechanism of C/EBPβ in LN remain unclear. In this investigation, glomerular podocytes treated with LN serum and MRL/lpr mice were employed as in vivo and in vitro models of LN, respectively. In vivo , the expression of C/EBPβ isoforms was detected in kidney specimens of humans and mice with LN. Then we assessed the effect of C/EBPβ inhibition on renal structure and function by injecting RNAi adeno-associated virus of C/EBPβ shRNA into MRL/lpr mice. In vitro , glomerular podocytes were treated with LN serum and C/EBPβ siRNA to explore the role of C/EBPβ in the activation of the AIM2 inflammasome and podocyte injury. C/EBPβ-LAP and C/EBPβ-LIP were significantly overexpressed in kidney tissue samples from LN patients and mice, and C/EBPβ inhibition significantly alleviated renal function damage and ameliorated renal structural deficiencies. Inflammatory pathways downstream from the AIM2 inflammasome could be suppressed by C/EBPβ knockdown. Furthermore, the upregulation of C/EBPβ-LAP could activate the AIM2 inflammasome and podocyte pyroptosis by binding to the promoters of AIM2 and CASPASE1 to enhance their expression, and the knockdown of AIM2 or (and) caspase-1 reversed the effects of C/EBPβ-LAP overexpression. Interestingly, C/EBPβ-LIP overexpression could transcriptionally inhibit IRAG and promote Ca2+ release-mediated activation of the AIM2 inflammasome. This finding suggests that C/EBPβ is not only involved in the regulation of the expression of key proteins of the AIM2 inflammasome but also affects the polymerization of key proteins of the AIM2 inflammasome through the regulation of Ca2+ release. In conclusion, this study provides a new idea for studying the regulatory mechanism of C/EBPβ and provides a theoretical basis for the early diagnosis and treatment of LN in the future. © 2023 The Pathological Society of Great Britain and Ireland.
C/EBPβ亚型对狼疮性肾炎肾损伤足细胞焦下垂的特异性调控
作为系统性红斑狼疮(SLE)预后的重要因素,狼疮性肾炎(LN)可加速SLE患者向慢性肾脏疾病甚至终末期肾脏疾病的转变。足细胞现在似乎是LN的一个可能的直接靶点,此外还容易受到免疫复合物和炎症过程诱导的肾小球毛细血管损伤的附带损伤。NLRP3炎症小体受CCAAT/增强子结合蛋白β(C/EBPβ)的调节,参与SLE的发病机制。然而,C/EBPβ在LN中的作用和机制尚不清楚。在本研究中,用LN血清和MRL/lpr小鼠处理的肾小球足细胞分别用作LN的体内和体外模型。在体内,在LN患者和小鼠的肾脏标本中检测到C/EBPβ亚型的表达。然后,我们通过将C/EBPβshRNA的RNAi腺相关病毒注射到MRL/lpr小鼠中来评估C/EBPα抑制对肾脏结构和功能的影响。在体外,用LN血清和C/EBPβsiRNA处理肾小球足细胞,以探讨C/EBPα在AIM2炎症小体激活和足细胞损伤中的作用。在LN患者和小鼠的肾组织样本中,C/EBPβ-LAP和C/EBPα-LIP显著过表达,并且C/EBP?抑制显著减轻肾功能损伤和改善肾结构缺陷。敲低C/EBPβ可以抑制AIM2炎症小体下游的炎症途径。此外,C/EBPβ-LAP的上调可以通过与AIM2和CASPASE1的启动子结合来增强其表达,从而激活AIM2炎症小体和足细胞焦下垂,并且AIM2或(和)胱天蛋白酶1的敲低逆转了C/EBPα-LAP过表达的影响。有趣的是,C/EBPβ-LIP过表达可以转录抑制IRAG并促进Ca2+释放介导的AIM2炎症小体的激活。这一发现表明,C/EBPβ不仅参与调节AIM2炎症小体关键蛋白的表达,而且通过调节Ca2+的释放影响AIM2炎症体关键蛋白的聚合。总之,本研究为研究C/EBPβ的调节机制提供了新的思路,为今后LN的早期诊断和治疗提供了理论依据。©2023大不列颠及爱尔兰病理学会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。